bDepartment of Rehabilitation Medicine;
cDepartment of Laboratory Medicine;
dInstitute for Bio-Medical Convergence;
eCell Therapy Center, Catholic Kwandong University International St. Mary’s Hospital, Incheon, South Korea
Keywords: Mesenchymal stromal cells; Adipose tissue; Poliomyelitis.
Poliomyelitis is a viral infection that affects motor neurons and causes permanent muscle weakness. Though polio has been eradicated in the developed world owing to the introduction of vaccine, many of aged survivors suffer from further deterioration of motor function which is called post-polio syndrome.There are no restorative treatments for this condition so far except applying orthotics and assistive devices to maintain activity [3]. Because of the debilitating nature of the disease and impending health situation of the polio survivors who are getting older, claim for use of stem cell therapy for this population was raised [4]. The target for stem cell could be either nerve cell or muscle. Adipose tissue-derived stem cells have been investigated for the treatment of skeletal muscle injury [5] and motor neuron disease [6]. However, no trials of stem cell therapy for poliomyelitis have been reported yet.
We assumed that intramuscular injection of SVF derived from autologous adipose tissue might enhance muscle function of poliomyelitis subjects by either myogenic or paracrine effect of mesenchymal stem cells in the SVF.In this brief report, we present four participants who complained of gait disturbance secondary to poliomyelitis since childhood, and had liposuction and intramuscular injection of freshly isolated SVF.
Liposuction procedure was performed without producing any significant adverse events. From the adipose tissue extract of 50ml, 1.09x107 stromal cells were isolated. The number of colony forming unit was one. Cells were diluted with 10ml normal saline and injected into right rectus femorismuscle.
After the injection, he felt his gait posture was improved as limping diminished and found himself more vitalized and less fatigued. Objective clinical evaluation was not performed for this case.
About 10 months later, he felt this healthy feeling began to hold back. However, he said he would recommend SVF injection to other post-polio survivors.
Liposuction procedure was performed without producing any significant adverse events. From the adipose tissue extract of 35ml, 1.74x107 stromal cells (viability 63%) were isolated. The number of colony forming unitwas five.Cells were diluted with 20ml normal saline and injected into bilateral rectus femoris,gluteus medius, adductor magnus and biceps femorismuscles.
After he had intramuscular SVF injection, he became to be able to walk without crutches. He reported that his lower limb muscle strength was improved after the procedure from 20% to 30% of normal in his subjective sense. Objective clinical evaluation was not performed for this case.
A few months later, he was still able to walk with a single cane.
Liposuction procedure was performed without producing any significant adverse events. From the adipose tissue extract of 50ml, 6.07x107 stromal cells (viability 72%) were isolated (Figure. 1). The number of colony forming unitwas eighteen. Cells were diluted with 24ml normal saline and injected into bilateral gluteus medius, rectus femoris, biceps femoris, right biceps brachii, triceps brachii, tibialis anterior and gastrocnemius muscles.
After the injection, he reported that his muscle strength was increased and general well-being sense improved. He also reported that he felt increased muscle strength when walking as well as driving a car.
For objective outcome evaluation, muscle strength, physical performance and skeletal muscle mass were measured before treatment, 2 weeks, 1 month, 2 months, and 3 months after treatment.
Physical performance was measured by Short Physical Performance Battery(SPPB) [7], which consists of balance test, gait speed test, and chair stand test. The SPPB recorded full score at both before and after treatment, however, gait speed showed increasing trend from 3.75 sec/4 meter walk to 3.66, 3.21, 2.97, and 3.01 at 2 weeks, 1 month, 2 months, and 3 months after injection respectively.
Lean body mass measured by dual x-ray absorptiometry did not show notable changes.
Liposuction procedure was performed without producing any significant adverse events. From the adipose tissue extract of 100ml, 3.15x107 stromal cells (viability 80%) were isolated. The number of colony forming unit was three. Cells were diluted with 20ml normal saline and injected into right rectus femoris and gluteus medius muscles.
After the injection, he denied any subjectively notable changes. He didn’t report any feeling of increased strength or vitality.
For objective outcome evaluation, muscle strength, physical performance, skeletal muscle mass, and quality of life were measured before treatment, 2 weeks, 1 month, 2 months, 3 months and 6 months after treatment.
Muscle strength measured by hand-held dynamometer did not show consistent changes. Physical performance measured by SPPB recorded 9(balance test 2, gait speed test 3, and chair stand test 4) before treatment and increased to 11(balance test 4, gait speed test 3, and chair stand test 4) after treatment. Walking ability was measured by 10 meter walking test and 6 minutes walking test. Comfortable walking speed measured during 10 meter walking test increased from 0.66 m/s before treatment to 0.74, 0.84, and 0.97 m/s at 2 weeks, 3 months, and 6 months after injection respectively, while fast walking speed measured during 6 minute walking test showed only slight increase from 1.00 m/s to 1.03 m/s after treatment (Fig. 2C).
Lean body mass measured by dual x-ray absorptiometry did not show consistentchanges. Health-related quality of life measured by WHO quality of life-BREF did not show notable changes either in all domains.
The findings of each case are summarized in Table 1.
Case |
Sex |
Age |
Affected limb |
Adipose tissue extract |
SVF cells: |
CFU |
Number of muscles injected |
Adverse events |
Subjective report of treatment effect |
Objective clinical outcome measures |
1 |
M |
56 |
Right lower limb |
50ml |
1.09x10^7 |
1 |
1 |
None |
Walking ability improved |
Not available |
2 |
M |
60 |
Both lower limbs |
100ml |
1.74x10^7 |
5 |
8 |
None |
Walking ability improved |
Not available |
3 |
M |
54 |
Both upper and lower limbs |
100ml |
6.07x10^7 |
18 |
10 |
None |
Muscle strength increased |
Muscle strength increased (dynamometer) |
4 |
M |
56 |
Right lower limb |
100ml |
3.15x10^7 |
2 |
2 |
None |
No remarkable change |
Gait speed increased |
Clinical applications of SVF have been attempted to various conditions such as chronic wounds, osteoarthritis, Crohn’s disease, multiple sclerosis and other orthopaedic and neurologic conditions [14]. Their final results are not available yet. Though it’s still at investigative stage, SVF’s potential for clinical application would be very wide. However, quality control and safety issues of SVF extraction and isolation procedure are raised [15], and lack of regulatory guideline remains to be solved [16].
Since its introduction more than a decade ago, stem cell therapy raised expectation for potential benefit among subjects with poliomyelitis just as those with other kinds of disabilities. To our knowledge, this is the first report of stem cell therapy applied to individuals with poliomyelitis. Although there’s no established stem cell therapy for post-polio survivors yet, we assumed autologous adipose tissue derived SVF might be a clinically applicable stem cell therapy for this population.
Extraction of adipose tissue from abdominal subcutaneous fat layer and intramuscular injection of SVF was successfully performed without producing any significant adverse event in our participants. SVF cell isolation was satisfactory to yield sufficient cell counts with acceptable viability and colony forming units. The amount of progenitor cells in SVF cells was assessed by the number of colony forming unit.In this study, 10~60 million stromal cells per subject were isolated and roughly 2~15 million stromal cells were injected into a muscle. We could not find relationship between injected cell dose and clinical effect. There may be factors other than cell count that are related with clinical effect, such as genetic predisposition, exercise and behavioural factors, etc.We suppose our intervention procedure is safe and feasible in subjects with poliomyelitis.
The cases in thisreport suggest possibility of improving muscle function in poliomyelitis subjects by intramuscular injection of autologous adipose tissue derived mesenchymal stromal cells. The mechanism of increased muscle strength could be either local myogenic effect or systemic paracrine effect, or both. We call for further research to explore the myogenic potential of SVF so that it can be considered as one treatment option for those who have muscular weakness secondary to various kinds of neuromuscular diseases including post-polio syndrome.
- Meregalli M, Farini A, Belicchi M, Parolini D, Cassinelli L, Razini P, et al. Perspectives of stem cell therapy in Duchenne muscular dystrophy. FEBS J.2013;280(17):4251-4262. doi: 10.1111/febs.12083
- De Francesco F, Ricci G, D'Andrea F, Nicoletti GF and Ferraro GA. Human Adipose Stem Cells: From Bench to Bedside. Tissue Eng Part B Rev. 2015;21:572-584. doi: 10.1089/ten.TEB.2014.0608
- Khan F. Rehabilitation for postpolio sequelae. Aust Fam Physician.2004;33:621-624.
- Bollenbach EP. Stem cell therapy for post-polio syndrome. Post-polio Health. 2003;19(4):1-3.
- Peçanha R, Bagno LL, Ribeiro MB, Robottom Ferreira AB, Moraes MO, Zapata-Sudo G, et al. Adipose-derived stem-cell treatment of skeletal muscle injury.J Bone Joint Surg Am.2012;94:609-617.doi: 10.2106/JBJS.K.00351.
- Kim KS, Lee HJ, An J, Kim YB, Ra JC, Lim I, et al. Transplantation of human adipose tissue-derived stem cells delays clinical onset and prolongs life span in ALS mouse model.Cell Transplant. 2014; 23(12): 1585-1597. doi: 10.3727/096368913X673450
- Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:M85-M94.doi: 10.1093/geronj/49.2.M85
- Riordan NH, Ichim TE, Min WP, Wang H, Solano F, Lara F, et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med.2009;7:29. doi: 10.1186/1479-5876-7-29
- Han S, Sun HM, Hwang KC and Kim SW. Adipose-Derived Stromal Vascular Fraction Cells: Update on Clinical Utility and Efficacy. Crit Rev Eukaryot Gene Expr. 2015;25:145-152.
- Chen YJ, Liu HY, Chang YT, Cheng YH, Mersmann HJ, Kuo WH, et al. Isolation and Differentiation of Adipose-Derived Stem Cells from Porcine Subcutaneous Adipose Tissues.J Vis Exp. 2016; 109:e53886, doi: 10.3791/53886
- Duscher D, Luan A, Rennert RC, Atashroo D, Maan ZN, Brett EA, et al. Suction assisted liposuction does not impair the regenerative potential of adipose derived stem cells. J Transl Med. 2016;14:126. doi: 10.1186/s12967-016-0881-1
- Bright R, Bright M, Bright P, Hayne S and Thomas WD. Migraine and tension-type headache treated with stromal vascular fraction: a case series. J Med Case Rep. 2014;8:237. doi: 10.1186/1752-1947-8-237
- Charles-de-Sa L, Gontijo-de-Amorim NF, Maeda Takiya C, Borojevic R, Benati D, Bernardi P, et al. Antiaging treatment of the facial skin by fat graft and adipose-derived stem cells. Plast Reconstr Surg. 2015;135:999-1009. doi: 10.1097/PRS.0000000000001123
- Nguyen A, Guo J, Banyard DA, Fadavi D, Toranto JD, Wirth GA, et al. Stromal vascular fraction: A regenerative reality? Part 1: Current concepts and review of the literature.J Plast Reconstr Aesthet Surg. 2016; 69(2): 170-179. doi: 10.1016/j.bjps.2015.10.015
- Lockhart RA, Aronowitz JA, Dos-Anjos Vilaboa S.Use of Freshly Isolated Human Adipose Stromal Cells for Clinical Applications.Aesthet Surg J. 2017,1;37(suppl_3):S4-S8. doi: 10.1093/asj/sjw270
- Bora P and Majumdar AS. Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation.Stem Cell Res Ther.2017,15;8(1):145. doi: 10.1186/s13287-017-0598-y